Development of radioresistance in drug resistant human MCF-7 breast cancer cells

Journal of Radiotherapy in Practice

Volumn 8, Issue 4, 2009, Pages 207-213

  Kars, Meltem Demirel ^a   Iseri, Özlem Darcansoy ^a   Ural, Ali Ugur ^b   Avcu, Ferit ^b   Beyzadeoglu, Murat ^b   Dirican, Bahar ^b   Gündüz, Ufuk ^a,b  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

MCF 7; MDR1; Radioresistance; Real time PCR

Indexed keywords

ABC TRANSPORTER; DOCETAXEL; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE; ZOLEDRONIC ACID; ZOMERA;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; CROSS RESISTANCE; GAMMA IRRADIATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION;

EID: 74549141414     PISSN: 14603969     EISSN: 14671131     Source Type: Journal    
DOI: 10.1017/S1460396909990070     Document Type: Article

References (30)

1. Danielson B, Winget M, Gao Z, Murray B, Pearcey R. Palliative radiotherapy for women with breast cancer. Clin Oncol 2008; 20: 506-512.
2. Polyak K. On the birth of breast cancer. BBA 2001; 1552: 1-13.
3. Gluck S. The prevention and management of distant metastases in women with breast cancer. Cancer Invest 2007; 25: 6-13.
4. Cameron D. Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. Breast 2003; 2: 22-29.
5. Jameel JKA, Rao VSR, Cawkwell L, Drew PJ. Radioresistance in carcinoma of the breast. Breast 2004; 13: 452-460.
6. Dalton WS. Mechanisms of drug resistance in hematologic malignancies. Semin Hematol 1997; 34: 3-8.
7. Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 1989; 16: 156-165.
8. KrögerN, AchterrathW, Becker HS, Mross K, Zander AR. Current options in treatment of anthracycline resistant breast cancer. Cancer Treat Rev 1999; 2: 279-291.
9. Stewart DJ, Raphorst GP, Yau J. Active vs passive resistance, dose-response relationships, high-dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs 1996; 14: 115-130.
10. Giannakakau P, Gussio R, Nogales E, Downing K, Fojo T. A common pharmacophore for epothilone and taxanes: molecular basis of drug resistance conferred by tubulin mutations in human cancer cells. Proc Nat Acad Sci USA 2000; 97: 2904-2909.
11. Chan S, Friedrichs K, Noel D et al., Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354.
12. Lobert S, Vulevic B, Correia JJ. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 1996; 35: 6806-6814.
13. Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G, Silvestrini R. Expression of P-glycoprotein in breast cancer tissue and in-vitro resistance to doxorubicin and vincristine. Eur J Cancer 1991; 27: 155-158.
14. Slovak ML, Hoeltge GA, Dalton WS, Trent JM. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res 1988; 48: 2793-2797.
15. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459-1468.
16. Ural AU, Avcu F. Evolving therapeutic role of bisphosphonates in multiple myeloma. Br J Cancer 2005; 93: 267-268.
17. Avcu F, Ural AU, Yilmaz MI et al., The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane. Eur J Haematol 2005; 74: 496-500.
18. Bacus SS, Kiguchi K, Chin D, King CR, Huberman E. Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol Carcinogen 1990; 3: 350-362.
19. Kars MD, I̧seri OD, Gunduz U, Molnar J. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines. Chemotherapy 2008: 54: 194-200.
20. Kars MD, I̧seri OD, Ural AU, Gündüz U. In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Res 2007; 27: 4031-4037.
21. Eskiocak U, I̧seri OD, Kars MD, Bi̧cer A, Gunduz U. Effect of doxorubicin on telomerase activity and apoptotic gene expression in doxorubicin-resistant and -sensitive MCF-7 cells: an experimental study. Chemotherapy 2008; 54: 209-216.
22. Ries LAG, Melbert D, Krapcho M et al., SEER Cancer Stat Rev. 1975-2004. National Cancer Institute. Bethesda, MD.
23. Widakowich C, Azambula E, Gil T, Dinh P, Awada A, Gebhart MP. Molecular targeted therapies in breast cancer: where are we now? Int J Biochem Cell Biol 2007; 39: 1375-1387.
24. Mc Donald SL, Stevenson DAJ, Moir SE et al. Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. Eur J Cancer 2005; 41: 1086-1094.
25. Marty M, Extra JM, Cottu PH, Espie M. Prospects with docetaxel in the treatment of patients with breast cancer. Eur J Cancer 1997; 33: 26-29.
26. Adamo V, Iorfida M, Montalto E et al. Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. Ann Oncol 2007; 18: 53-57.
27. Helland A, Johnsen H, Froyland C et al. Radiationinduced effects on gene expression: an in vivo study on breast cancer. Radiother Oncol 2006; 80: 230-235.
28. Amundson SA, Grace MB, McLeland CB et al. Human in vivo radiation-induced biomarkers: gene expression changes in radiotherapy patients. Cancer Res 2004; 64: 6368-6371.
29. Rodningen OK, Overgaard J, Alsner J, Hastie T, Dale BAL. Microarray analysis of the transcriptional response to single or multiple doses of ionizing radiation in human subcutaneous fibroblasts. Radiother Oncol 2005; 77: 231-240.
30. Ural AU, Avcu F, Candir M, Guden M, Ozcan MA. In vitro synergistic cytoreductive affects of zoledronic acid radiation on breast cancer cells. Breast Cancer Res 2006; 8: R52.